Manufactured Object – Page 24

Pharmaceutical Companies Prevail in 340B Case as Appeals Court Upholds Discount Restrictions

11 months ago talkbio0Tagged 340B, Appeals Court, Clinic, discounts, drugmakers, Health care facility, healthcare, Hospitals, Programs - Publication Format

340B program, drugmakers, discounts, Appeals Court, ruling, healthcare, pharmaceuticals, hospitals, clinics.

Evotec Discontinues Gene Therapy Operations, Shuts Down Austria Facility

11 months ago talkbio0Tagged Austria, Biotechnology, business operations, development aspects, Evotec, Facility (object), gene therapy, Reparative closure, research, strategic decision

Evotec, gene therapy, Austria, facility closure, strategic decision, business operations, research and development, biotechnology

AstraZeneca’s Billion-Dollar Bet: Accelerating Biopharma Innovation in China

11 months ago talkbio0Tagged AstraZeneca, Biopharma, China sales, Clinical Trials, Collaboration, development aspects, Drug Industry, Health care facility, innovation, Investments, partnerships, research

AstraZeneca, China sales, biopharma innovation, investment, research and development, healthcare market, pharmaceutical industry, clinical trials, partnerships, collaborations.

AstraZeneca Invests $1.5 Billion in Singapore for Comprehensive Antibody-Drug Conjugate Manufacturing

11 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, Investments, Manufacture, production, Singapore

AstraZeneca, Singapore, antibody-drug conjugate (ADC), manufacturing, investment, biotechnology, pharmaceuticals, end-to-end production, cancer treatment.

AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility

11 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, expansion, Facility (object), Generalized, innovation, Investments, Singapore

AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.